Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 601-325-6 | CAS number: 114772-38-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 September 2013 - 23 April 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Test method according to OECD Guideline 429. GLP study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- methyl 4'-(bromomethyl)-[1,1'-biphenyl]-2-carboxylate
- EC Number:
- 601-325-6
- Cas Number:
- 114772-38-2
- Molecular formula:
- C15H13BrO2
- IUPAC Name:
- methyl 4'-(bromomethyl)-[1,1'-biphenyl]-2-carboxylate
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material: Methyl 2-[4-(bromomethyl)phenyl]benzoate
- Physical state: white or almost white powder
- Lot/batch No.: M09487R
Constituent 1
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- other: CBA/J Rj
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: ELEVAGE JANVIER, Route des Chènes Secs B.P. 4105, 53940 LE GENEST-ST-ISLE, France
- Age at study initiation: 9 weeks old
- Weight at study initiation: 20.1-22.9 g
- Housing: Group caging / mice were provided with glass tunnel-tubes. Cage type: Type II. polypropylene / polycarbonate.
- Diet (e.g. ad libitum): ad libitum, ssniff® SM Rat/Mouse – “Breeding & Maintenance, 15 mm, autoclavable Complete diet for rats/mice”
- Water (e.g. ad libitum): ad libitum, tap water
- Acclimation period: al leaste 14 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 30-70 %
- Air changes (per hr): 15-20 air exchanges/hour
- Photoperiod (hrs dark / hrs light): 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Study design: in vivo (LLNA)
- Vehicle:
- other: N,N-dimethylformamide (DMF)
- Concentration:
- 0.25, 0.1 and 0.05 % (w/v).
- No. of animals per dose:
- 4 animals per dose.
- Details on study design:
- RANGE FINDING TESTS:
- Compound solubility: The solubility of the test item was examined in a short Preliminary Compatibility Test. Based on physical characteristics of the test item, 100% (w/v) concentration in DMF was achievable.
- Preliminary Irritation/Toxicity Test: Four preliminary irritation/toxicity tests were performed at of 100 and 50 % (w/v) (2 animals/dose), 25 and 10 % (w/v) (2 animals/dose), 5, 2.5, 1 and 0.5 % (w/v) (1 animal/dose) and 0.25, 0.1, 0.05 and 0.025 % (w/v) (1 animal/dose). The preliminary experiments were conducted in a similar experimental manner to the main study, but they were terminated on Day 6 with a body weight measurement and the radioactive proliferation assay was not performed. All mice were observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Both ears of each mouse were observed for erythema and scored. Ear thickness was also measured using a thickness gauge on Day 1 (pre-dose), Day 3 (approximately 48 hours after the first dose) and Day 6. Additional quantification of the ear thickness was performed by ear punch weight determination after the euthanasia of the experimental animals. Based on the observations recorded in the preliminary tests, 100, 50, 25, 10, 5, 2.5, 1 and 0.5 % (w/v) doses were considered too high based on the increased ear thickness values indicating excessive local skin irritation. Therefore, 0.25, 0.1, and 0.05 % (w/v) doses were examined in the main test.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Criteria used to consider a positive response: The test item is regarded as a sensitizer if both of the following criteria are fulfilled:
*That exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than recorded in
control mice, as indicated by the stimulation index.
*The data are compatible with a conventional dose response, although allowance must be made for either local toxicity or immunological suppression.
TREATMENT PREPARATION AND ADMINISTRATION:
During the study, animals were topically dosed with 25 µL of the appropriate formulation using a pipette on the dorsal surface of each ear. Each animal was dosed once a day for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6. On day 6, each mouse received an injection of 250µl of sterile PBS (phosphate buffered saline) containing approx. 20 µCi of 3HTdR. Five hours later, the mice were euthanized and the auricular lymph nodes were extracted from the animals. A single cell suspension (SCS) of pooled lymph node cells (LNCs) was prepared and the samples were prepared to be examined in a β-scintillation counter.
OBSERVATIONS:
During the study (Day 1 to Day 6) each animal was observed daily for any clinical signs, including local irritation and systemic toxicity. Clinical observations were performed twice a day (before and after treatments) on Days 1, 2 and 3 and once daily on Days 4, 5 and 6. Individual body weights were recorded on Day 1 (beginning of the test) and on Day 6 (prior to 3HTdR injection).
EVALUATION OF RESULTS:
Radioactive disintegrations per minute (DPM) was measured for each pooled group of nodes and corrected with the background DPM value. The results were expressed as “DPN” (DPM divided by the number of lymph nodes). Stimulation index (SI = DPN value of a treated group divided by the DPN value of the negative control group) for each treatment group was also calculated. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
Results and discussion
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- SI
- Remarks on result:
- other: The stimulation index values were 62.3, 22.3 and 8.7 at concentrations of 0.25, 010 and 0.05 % (w/v), respectively. The calculated EC3 value was calculated to be 0.037% (w/v).
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: Test item 0.25 % (w/v) in DMF: 91185.5 DPM Test item 0.10 % (w/v) in DMF: 32711.5 DPM Test item 0.05 % (w/v) in DMF: 12744.5 DPM
Any other information on results incl. tables
Clinical observation:
No mortality or systemic clinical signs were observed during the study. There were no indications of any irritancy at the site of application. The ear thickness values and the revealing ear punch weights were within the historical control range in all test item treated dose groups.
Body weight:
No treatment related effects were observed on body weights.
Proliferation assay:
Test Group Name |
Measured DPM / group |
DPM |
Number |
DPN |
Stimulation Index |
Background (5 % (w/v) TCA) |
31/36 |
- |
- |
- |
- |
(-) control (DMF) |
1498 |
1464.5 |
8 |
183.1 |
1.0 |
Test item 0.25 % (w/v) in DMF |
91219 |
91185.5 |
8 |
11398.2 |
62.3 |
Test item 0.10 % (w/v) in DMF |
32745 |
32711.5 |
8 |
4088.9 |
22.3 |
Test item 0.05 % (w/v) in DMF |
12778 |
12744.5 |
8 |
1593.1 |
8.7 |
(+) control (25 % (w/v) HCA in DMF) |
21454 |
21420.5 |
8 |
2677.6 |
14.6 |
The appearance of the lymph nodes was normal in the negative (vehicle) control group. Larger than normal lymph nodes were observed in the positive control group, in the 0.25% (w/v) dose group and for three animals in the 0.10% (w/v) group. Slightly enlarged lymph nodes were detected in the 0.05 % (w/v) group and for one animals in the 0.10% (w/v) group.
The stimulation index values were 62.3, 22.3 and 8.7 at concentrations of 0.25, 0.10 and 0.05% (w/v), respectively.
The calculated EC3 value was calculated 0.037% (w/v).
Applicant's summary and conclusion
- Interpretation of results:
- sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The test item showed to have sensitisation potential (sensitizer) in the Local Lymph Node Assay. The stimulation index values were 62.3, 22.3 and 8.7 at concentrations of 0.25, 0.10 and 0.05% (w/v), respectively. The calculated EC3 value was calculated to be 0.037% (w/v).
- Executive summary:
The skin sensitisation test following dermal exposure was performed according to OECD Guideline 429 and EU method B.42 (GLP study). Based on the results of the Preliminary Compatibility Test, the test item was formulated in N,N-dimethylformamide (DMF) at a highest achievable concentration of 100 % (w/v). The Preliminary Irritation / Toxicity Test was performed in CBA/J Rj mice using twelve doses: 100, 50, 25, 10, 5, 2.5, 1, 0.5, 0.25, 0.10, 0.05 and 0.025% (w/v) in DMF. The 0.25 % (w/v) was selected as top dose for the main test. Twenty female CBA/J Rj mice were allocated to five groups of four animals each in the main test. Three groups received the test item at 0.25, 0.10 and 0.05 % (w/v) concentrations, the negative control group received the vehicle (DMF) and the positive control group received 25 % (w/v) HCA (dissolved in DMF). The test item solutions were applied on the dorsal surface of ears of experimental animals (25 μL/ear) for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6. On Day 6, the cell proliferation in the local lymph nodes was measured by incorporation of tritiated methyl thymidine (3HTdR) and the values obtained were used to calculate stimulation indices (SI). No mortality or systemic clinical signs were observed during the study. There were no indications of any irritancy at the site of application. The ear thickness values and the revealing ear punch weights were 62.3, 22.3 and 8.7 at concentrations of 0.25, 0.10 and 0.05% (w/v), respectively. The calculated EC3 value was 0.037% (w/v). All validity criteria were fulfilled. In conclusion, the test item showed to have sensitisation potential (sensitizer) in the Local Lymph Node Assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.